FDA Watch: DOGE Changes at FDA Upend Approval Processes, Observers Say
Pre-submission and Q-Submission meetings apparently have been halted, for now
Pre-submission and Q-Submission meetings apparently have been halted, for now
Although the timelines have been extended several times, IVDR complexity has created a concerning bottleneck in the approval process
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
Understanding the process and implementing proper procedures is the key to ensuring compliance when reporting such events
How the current FDA AI/ML device regulations may be impeding innovation in the clinical lab
FDA seems determined to push ahead with final rule, regardless of CDRH director’s departure, hiring of replacement.
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
The company is hiring at least 100 sales representatives this year to spread awareness and uptake of its recently FDA-approved Shield test
A lawsuit by a group of herring fishermen upended 40 years of legal precedent regarding how federal agencies interpret statutes